XENiOS® Will Seek Regulatory Approval for i-lung®

XENiOS®, a commercial-stage medical device company, announced today it expects to receive CE-marking for its i-lung® device within 18 months. XENIOS expects to launch i-lung® in 2017. Currently available devices lack durability and wearability. Additionally, the size of current systems restricts patient mobility and limits quality of life. i-lung represents an innovative and first-of-its-kind fully wearable artificial lung for long-term use in a hospital environment.

"The availability of i-lung will open the door to significant medical progress for respiratory support. For many patients in lung failure currently undergoing invasive mechanical ventilation, the use of i-lung is designed to avoid sedation and immobility, thus creating active, self-managed patients," said Georg Matheis, MD, Managing Director & Founder of XENIOS. "In addition, i-lung is designed to be used to bridge the waiting time for a donor organ (bridge-to-lung-transplant)."

"Of special note," added Juergen Boehm, MD, Managing Director of Xenios, "i-lung paves the way for XENiOS to continue development of a bioartificial lung for use by patients outside of a hospital environment analogous to current artificial heart protocols, which will represent a paradigm shift in the approach to long-term respiratory support."

i-lung is the result of the successful completion of the AmbuLung project, a three-year R&D consortium project funded by the European Union’s FP7 Program that developed the basis for i-lung, the world’s first-of-its-kind wearable artificial lung. In addition to XENiOS, the consortium included Fraunhofer IGB (Stuttgart, Germany); Imperial College of Science, Technology and Medicine (London, UK); and, the University of Florence (Italy).

"We are forever indebted to the vision and the work of Professor Dame Julia Polak, who passed away last year," said Dr. Matheis. "Julia and I co-founded the i-lung project, and because of her enormous contribution i-lung is now a reality, and a bioartificial next-gen of i-lung on the horizon." The author of some 1,000 original papers, 115 review articles and editor or author of 25 books, Julia Polak, MD, PhD, was one of the most widely cited researchers in her field, and had undergone a heart lung transplant. She served on several national and international tissue engineering and stem cell advisory panels, and was the European editor of the journal Tissue Engineering.

Funding for the commercialization of i-LUNG® has already been procured. XENIOS announced in September 2015 that it received an eight-figures cash infusion from existing investors, in part to fund CE-marking and launch of i-LUNG, led by ZFHN, one of the largest Single Family Offices in Germany investing in start-up companies.

About XENiOS®
XENiOS AG is a privately held medical technology company that is comprised of two product brands, novalung® and i–cor®, that run on a single XENiOS® console. The XENIOS platform is designed to provide at least four essential advantages with its minimally invasive lung and heart therapies: (1) patients are awake and mobile;(2) self-actuated patients facilitate improved outcomes; (3) there is no ventilator-associated lung injury or pneumonia; (4) additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.

Most Popular Now

Patient Care can Improve with Technology…

A significant part of the American Reinvestment and Recovery Act was the $25 billion invested in health information technology (IT) to improve quality, safety, efficiency in health care while also...

Read more

Medelinked Now Integrated with Microsoft…

Medelinked is now integrated with Microsoft Health and Band. The integration ensures that wellness summary data from Microsoft Health app and Band wearable is available in Medelinked to help users...

Read more

UK Health Show 2016 Partners with Highla…

GovNet Exhibitions has appointed Highland Marketing as its official partner to manage communications for the newly launched UK Health Show 2016. The show will bring together over 4,000 senior healthcare...

Read more

Seniors Embrace Social Technology

Contrary to popular belief, older adults enjoy emailing, instant messaging, Facebook and other forms of social technology. Not only that, but such online networking appears to reduce seniors' loneliness and...

Read more

Leading Digital Health Alliances Announc…

21 - 22 November 2016, Barcelona, Spain. The European Connected Health Alliance (ECHAlliance) and Personal Connected Health Alliance (PCHA) have signed a pivotal agreement to deliver key programme elements for the...

Read more

Big Data Europe Addresses Societal Chall…

Across society, from health to agriculture and transport, from energy to climate change and security, practitioners in every discipline recognise the potential of the enormous amounts of data being created...

Read more

Do Pokémon Go and augmented reality game…

The combination of augmented reality technology, geocaching, and other novel techniques to create innovative active video games (AVGs) has potential personal and public health implications, as discussed in the Editorial...

Read more

Nervecentre Launch Mobile Clinical Photo…

Nervecentre Software has launched a mobile clinical photography solution for nurses and doctors in hospitals. Fully integrated directly into the patient record, the mobile software is completely secure, compliant with...

Read more

in silico Clinical Trials: How Computer …

The term 'in silico clinical trials' refers to: "The use of individualised computer simulation in the development or regulatory evaluation of a medicinal product, medical device, or medical intervention...

Read more

Novartis Convenes Experts to Discuss New…

Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology...

Read more

10th European Medical Information and Co…

29 - 30 November 2016, Berlin, Germany The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical information professionals for medical information...

Read more

Pfizer Launches New "Moodivator…

Pfizer Inc. (NYSE:PFE) has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined